Biotech

Market growth 2024
#Biotech #Funding #GlobalData #Investment #Market reporting

Biotech funding recovery predicted for 2024

The biotech market is heading to recovery in 2024, following a marked downturn in investment in 2022 and 2023, according to healthcare industry professionals. A GlobalData survey ‘The State of the Biopharmaceutical Industry 2024’ found that more than 40% of the healthcare industry professionals surveyed globally expressed an optimistic or… Read More

#Business & Investment #News #Trending News

#AI #Biotech #Drug discovery #Generative AI

Genentech and NVIDIA partner to accelerate drug discovery with AI 

Biotechnology company Genentech has entered into a partnership with software group NVIDIA to use generative AI to discover and develop new therapeutics.   The collaboration will see experts from each company optimise and accelerate Genentech’s proprietary algorithms with goals to transform the discovery and development of new… Read More

#News

#AAV #Biotech #Drug discovery #Flow Cytometry #Life sciences

Biotechs to compete in Dragon’s Den session at BioProcessUK 

Life sciences companies are set to compete in a Dragon’s Den session at the BIA’s BioProcessUK event this month.   Taking place on day two of BIA BioProcess UK, the Dragon’s Den special session is focused on next generation analytical technologies and will see six companies compete for… Read More

#News

Human cell
#Appointment #Biotech #Drug discovery #Single-cell analysis

Cytomos appoints new director to assist commercialisation strategy  

Biotech company Cytomos has appointed a new Non-Executive Director in a bid to help accelerate plans to brings its cell analysis technology to market.   Dr Sharon Brownlow has joined as Non-Executive Director and will play a key role in helping Cytomos bring its Dielectric Spectroscopy (CDS)… Read More

#News

#Biotech #Cell and gene therapy #Clinical trials #Market reporting #Oncology

New podcast: A deep dive into US drug discovery

This is the latest episode of the free DDW narrated podcast, “What lies in the future for genomics and big data?”, which covers two articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “US biotech: Focus on positive growth… Read More

#News

Prize winner biotech
#Biotech #EIT Health Catapult 2023 #Immunyx

Israeli start-up wins EIT Health Catapult 2023 biotech category  

The winners of the EIT Health Catapult 2023 competition were announced at the Bits & Pretzels Conference, where Immunyx, a developer of immune modulating therapies for neutrophil based diseases, won in the biotech category.  The competition, an initiative by EIT Health, aims to accelerate the growth of… Read More

#News

#Biopharma #Biotech #Clarivate #Collaboration #Investment #Partnership

Biopharma investment drops by nearly 50% in 2022

Cell therapy, RNA technology, antibody drug conjugates and AI/machine learning are among the key areas of investment for pharma, according to a new report. Clarivate’s ‘Biopharma Dealmaking in 2023’ report examines how pharma companies are replenishing their pipelines as many face a steep patent cliff. The report combines data and… Read More

#Business & Investment #News #Trends & Analysis

Cancer cell
#Biotech #Cancer #iOnctura #Oncology #Pharmaceuticals

iOnctura expands pipeline and receives development grant 

iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumour survival pathways, has exercised an exclusive option with Clavius Pharmaceuticals, adding the novel oral TGF-β pathway inhibitor, IOA-359, to its pipeline.   IOnctura also announced it has, in collaboration with the… Read More

#News

Adcendo Lab
#Antibodies #Antibody drug conjugate (ADC) #Biotech #Drug development #Seed funding

Financing ensures development of Adcendo’s ADC asset 

Adcendo, a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, has completed a successful Series A extension financing round, raising a further €31 million, following the €51 million Series A financing in April 2021. Read More

#News